The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor UK News

London Launches £10m Programme to Fast-Track Heart, Diabetes and Obesity Care into the NHS

By aminah ·18 Nov 2026 ·4 min read
A doctor taking a patient's blood pressure with a cuff and stethoscope in a clinic
London has launched a £10 million programme to fast-track new treatments, medical devices and digital health tools for heart disease, diabetes and obesity from development into NHS care. The Frontier Innovation for Cardiometabolic Disease Programme is backed by £10 million from UK Research and Innovation's Local Innovation Partnerships Fund and supported by the Mayor of London. It was announced on 17 November 2026. The programme will support innovation at every stage, from early development through real-world testing to adoption in the NHS, private healthcare and international markets, helping patients across London benefit more quickly from new ways to prevent, detect and treat cardiometabolic disease. ## Two £5 million strands The initiative is made up of two complementary £5 million programmes. The Venture Builder programme will support the creation and growth of new ventures developing therapeutics, through the BioInnovation Institute, and medical technologies, through King's College London's London Institute for Healthcare Engineering, with King's Health Partners also contributing. The Validate and Scale programme is a partnership between private healthcare providers and the NHS. Led by UCLPartners, working with the Harley Street Health District, Imperial College Health Partners and the Health Innovation Network South London, it will let companies test new solutions to priority cardiometabolic challenges in real clinical settings, including in the Harley Street Health District, generating the evidence the NHS needs before adopting them. ## What the programme aims to deliver The Venture Builder programme expects to support more than 30 ventures, start four to six clinical trials and attract £200 million of private investment. The Validate and Scale project aims to engage more than 100 companies, give tailored support to at least 20 and help at least five breakout-stage companies validate and scale in London, leveraging £50 million to £100 million of private investment. Across the programme as a whole, partners aim to leverage up to £300 million in private investment and create up to 1,000 high-value jobs in London. ## Why heart and metabolic health matters in London Cardiovascular disease causes one in four deaths in London, according to Professor Kevin Fenton, regional director of public health for NHS England London, with the greatest burden falling on the most deprived communities. He said much of that burden was preventable, and that hundreds of thousands of Londoners are living with undiagnosed high blood pressure, putting them at unnecessary risk of heart attacks and strokes. Priorities for the programme span the full prevention pathway, from earlier identification of risk to interventions that reduce risk, support healthier lifestyles and improve the ongoing management of conditions such as high blood pressure, atrial fibrillation and high cholesterol. It will prioritise innovations that can reduce inequalities in cardiometabolic outcomes, with evidence generated across London's diverse populations. ## Part of a wider London life sciences package The £10 million programme sits within a £22 million London life sciences package announced by the Mayor of London, Sadiq Khan, on 16 November, the opening day of London Life Sciences Week. The package also includes £12 million for the London Quantum Cluster, led by UCL, Imperial College London and King's College London. Howard Dawber, Deputy Mayor of London for Business and Growth, said London was home to some of the world's leading hospitals, researchers and innovators, and that the collaboration could help pioneer new technologies and treatments, potentially saving lives and improving care for thousands of Londoners while strengthening the capital's life sciences sector. Dr Chris Laing, chief executive of UCLPartners, said the partnership was about drawing on London's world-leading assets to bring the most effective innovations to the NHS, so patients across the city could benefit faster from new technologies. ## The problem it is trying to solve In the UK, some promising health technologies never reach patients. Companies can struggle to gather the evidence the NHS and other healthcare providers need before they will adopt a new product. This initiative gives those companies a faster route to that evidence, by testing innovations with real patients in private hospitals and NHS settings. London's three health innovation networks will then help spread proven innovations across NHS services, so patients across the capital and beyond can benefit more quickly. ## FAQ **What is cardiometabolic disease?** Cardiometabolic disease covers conditions affecting the heart and metabolism, including heart disease, diabetes and obesity, as well as risk factors such as high blood pressure and high cholesterol. **Who is funding the programme?** The £10 million comes from UK Research and Innovation's Local Innovation Partnerships Fund, with support from the Mayor of London. **When will patients see the benefit?** The programme is designed to speed up testing and adoption, but individual treatments and devices will still need to complete trials and NHS assessment before they are offered to patients. Sources: [News-Medical](https://www.news-medical.net/news/20261117/c2a310-m-program-to-fast-track-cardiometabolic-innovation-from-lab-to-NHS.aspx); Mayor of London life sciences funding announcement, via [Barnet Live](https://www.barnetlive.co.uk/london-life-sciences-fund-22m-barnet/).